Skip to main content
Signal8

Editas Medicine, Inc. (EDIT)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Editas Medicine, Inc. logo

Editas Medicine, Inc.

NASDAQ:EDITHealthcare
Pre+1.95%$2.62
Close$2.57+0.78%AH$2.57+1.95%since
Mkt Cap$394.7M
Float148.82M
O/S153.58M
PM VOL4K sh
$ Vol≈$9K
RVOL0.24×
Inst Own78.3%
SI25.7%
Dilution
Editas Medicine, Inc. logoNASDAQ:EDITPre$2.62+1.95%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 20262.552.632.482.571,716,920
Nov 5, 20262.682.682.412.552,098,709
Nov 4, 20262.702.792.612.722,368,804
Nov 3, 20262.612.712.572.601,756,655
Nov 2, 20262.712.782.552.571,236,855
Oct 30, 20262.892.922.602.672,909,228
Oct 29, 20262.942.982.862.933,226,683
Oct 28, 20262.592.962.542.954,430,078
Oct 27, 20262.412.612.372.603,079,367
Oct 26, 20262.392.442.362.401,350,905
Oct 23, 20262.442.452.302.401,313,713
Oct 22, 20262.472.582.452.491,066,487
Oct 21, 20262.592.602.502.511,139,427
Oct 20, 20262.402.672.352.582,266,489
Oct 19, 20262.382.432.272.422,010,948
Oct 16, 20262.442.472.332.351,552,415
Oct 15, 20262.262.462.252.441,859,726
Oct 14, 20262.442.482.252.272,829,030
Oct 13, 20262.732.732.442.442,453,761
Oct 12, 20262.902.912.732.751,297,454
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
14
HOLD
9
SELL
2
TOTAL25
Insider Trades
InsiderTypeShares
O'Neill Gilmore Neil profile photoO'Neill Gilmore NeilGrant/Award43.6K
Burkly Linda profile photoBurkly LindaGrant/Award16.5K
Ory Daniel Scott profile photoOry Daniel ScottGrant/Award950.0K
O'Neill Gilmore Neil profile photoO'Neill Gilmore NeilSale5.1K
Burkly Linda profile photoBurkly LindaSale709
Parison Amy profile photoParison AmySale453
Shareholders
78.3%
Institutional
(218)
0.4%
Insiderⓘ
(5)
0.9%
5%+ Owners
(1)
20.4%
Unattributed (incl. retail)ⓘ
Institutional78.3%
Insider0.4%
5%+ Beneficial0.9%
Unattributed (incl. retail)20.4%
Sources: 13F, Form 4, 13D/13GO/S: 153.6M · as of 31 Jul 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

The company develops a proprietary gene editing platform based on CRISPR technology.

Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.

The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues.

It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease.

The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Key Metrics
Market Cap$394.70M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership78.27%

based on 153.58M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateFeb 3, 2016
Shares Outstanding153.58M
Authorized Shares
Float148.82M
52-Week Range
$1.66$3.94
$2.57(40th percentile)
Volume
Average Daily Volume2.10M
1.72M today vs 2.10M avg(-18%)

30d Avg

2.10M

60d Avg

2.76M

90d Avg

2.72M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...